Non-Hodgkin’s Lymphoma (NHL) Information Center
Each year in the United States, more than 66,000 people are diagnosed with non-Hodgkin’s lymphoma. Thanks to improvements in treatment, non-Hodgkin’s lymphoma patients are living longer. It is estimated that there are more than 400,000 non-Hodgkin’s lymphoma survivors living in the U.S. today.
Advances in chemotherapy, targeted therapy, and radiation therapy have all contributed to improved non-Hodgkin’s lymphoma survival. In addition, advances in supportive care have made non-Hodgkin’s lymphoma treatment more tolerable, leading to improved quality of life.
Understanding non-Hodgkin’s lymphoma treatment options, the role of different doctors specializing in the treatment of non-Hodgkin’s lymphoma, and how and when to access new and innovative non-Hodgkin’s lymphoma treatment options available through clinical trials is essential in order to achieve the best outcome from non-Hodgkin’s lymphoma treatment.
The Cancer Consultants Non-Hodgkin’s Lymphoma Information Center has been designed to help patients understand non-Hodgkin’s lymphoma and non-Hodgkin’s lymphoma treatment options while providing ongoing information, inspiration, support, and community to individuals affected by a diagnosis of non-Hodgkin’s lymphoma.
Headline NHL News 
CancerConnect Live Web Chat with Dr. Barrie Cassileth from Memorial Sloan-Kettering Cancer Center on Complementary Cancer Therapies on Thursday, November 17th at 6PM EST
Live Web Chat with Barrie R. Cassileth, PhD, Chief, Integrative Medicine Service;...
Organ Transplant Recipients Have Increased Cancer Risk
Twice the risk of the general population.
Chemotherapy During Pregnancy Not Linked with Developmental Problems in Kids
Pre-term delivery, however, poses a risk.
Non-Hodgkin's Lymphoma Tips
What is Genomics? You’ve probably heard of genetic testing for cancer susceptibility, but the more...
Know the Signs of Depression in Cancer Patients Because a significant number of cancer patients—an estimated 25 percent—experience...
Understanding Targeted Therapy for Non-Hodgkin’s Lymphoma Targeted therapies are anticancer drugs that are designed to treat cancer cells while...
Non-Hodgkin’s Lymphoma Management
Inspiration, Hope & Resources
On Top of the World: Climbing Everest & Beating Cancer Twice Sean Swarner is a master of setting a goal and achieving it. So when he...
Jack & Jill Late Stage Cancer Foundation Jon Albert, founder of the Jack & Jill Late Stage Cancer Foundation shows the...
Moving Bodies, Changing Lives Moving On Aerobics helps women regain joy of movement and physical fitness after...
Non-Hodgkin's Lymphoma Conference Coverage
ASCO 2009: Advances in Treatment of Aggressive B- and T-Cell Non-Hodgkin’s Lymphoma Date: May 29 – June 2, 2009 Location: Orlando, Florida Author: C. Dean Buckner,...
Non-Hodgkin’s Lymphoma Clinical Trials
COGANHL01P1 – A Pilot study to determine the Toxicity of the addition of Rituximab to the Inducation and Consolidation phases and the Addition of Rasburicase to the Reduction Phase in Children with Newly Diagnosed Advanced B-cell leukemia/lymphoma treated with LMB/FAB Therapy
SeaGenMarinerStudy – A Randomized Phase IIb Placebo-controlled study of R-ICE Chemotherapy (RItuximab, Ifosfamide, Carboplatin, and Etoposide) with and without SGN-40 (anti-CD40 humanized monoclonal antibody) for second-line treatment of patients with diffuse large B-cell lymphoma (DLBCL)
114-NH-301 – Phase III, Randomized, Double-blind Study of Glaiximab in combination with Rituximab compared with Rituximab in Combination with Placebo for the Treatment of Subjects with Relapsed or Refractory, Follicular Non-Hodgkin’s Lymphoma.
 |
 |
 |
 |
